Cash & Cash Equivalents
The latest quarterly cash is $480.40 Million with a quarter-over-quarter change of -32.91%. Cash and cash equivalents include currency, bank deposits, and highly liquid investments that can be quickly converted to cash.
PODD Cash
Reported quarterly cash and cash equivalents; no daily interpolation.
Current Cash
$480.40M
$480.40 Million
Quarter-over-Quarter Change
-32.91%
vs. $716.10M prior quarter
Historical Data
80
Quarters of data available
Quarterly Cash History
| Period | Cash | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $480.40M | $-235.70M | -32.91% |
| Q4 2025 | $716.10M | $-41.30M | -5.45% |
| Q3 2025 | $757.40M | $-235.50M | -23.72% |
| Q2 2025 | $992.90M | $-290.20M | -22.62% |
| Q1 2025 | $1.28B | +$329.70M | +34.58% |
| Q4 2024 | $953.40M | +$50.80M | +5.63% |
| Q3 2024 | $902.60M | +$187.10M | +26.15% |
| Q2 2024 | $715.50M | +$18.60M | +2.67% |
| Q1 2024 | $696.90M | +$46.20M | +7.10% |
| Q4 2023 | $650.70M | +$70.00M | +12.05% |
| Q3 2023 | $580.70M | +$23.90M | +4.29% |
| Q2 2023 | $556.80M | +$38.10M | +7.35% |
| Q1 2023 | $518.70M | $-105.20M | -16.86% |
| Q4 2022 | $623.90M | $-47.70M | -7.10% |
| Q3 2022 | $671.60M | +$13.00M | +1.97% |
| Q2 2022 | $658.60M | $-51.00M | -7.19% |
| Q1 2022 | $709.60M | $-82.00M | -10.36% |
| Q4 2021 | $791.60M | $-65.00M | -7.59% |
| Q3 2021 | $856.60M | +$2.00M | +0.23% |
| Q2 2021 | $854.60M | +$33.90M | +4.13% |
| Q1 2021 | $820.70M | $-86.50M | -9.53% |
| Q4 2020 | $907.20M | +$69.10M | +8.24% |
| Q3 2020 | $838.10M | +$59.00M | +7.57% |
| Q2 2020 | $779.10M | +$577.70M | +286.84% |
| Q1 2020 | $201.40M | $-2.30M | -1.13% |
| Q4 2019 | $203.70M | $-216.18M | -51.49% |
| Q3 2019 | $419.88M | +$300.01M | +250.29% |
| Q2 2019 | $119.87M | $-9.39M | -7.26% |
| Q1 2019 | $129.25M | +$15.35M | +13.47% |
| Q4 2018 | $113.91M | $-12.66M | -10.00% |
| Q3 2018 | $126.56M | $-9.68M | -7.11% |
| Q2 2018 | $136.25M | $-66.90M | -32.93% |
| Q1 2018 | $203.15M | $-69.43M | -25.47% |
| Q4 2017 | $272.58M | +$170.34M | +166.62% |
| Q3 2017 | $102.23M | +$28.75M | +39.12% |
| Q2 2017 | $73.49M | $-2.55M | -3.35% |
| Q1 2017 | $76.04M | $-61.14M | -44.57% |
| Q4 2016 | $137.17M | $-78.23M | -36.32% |
| Q3 2016 | $215.40M | +$104.14M | +93.59% |
| Q2 2016 | $111.27M | $-369,000 | -0.33% |
| Q1 2016 | $111.64M | $-11.04M | -9.00% |
| Q4 2015 | $122.67M | $-22.80M | -15.67% |
| Q3 2015 | $145.47M | +$330,000 | +0.23% |
| Q2 2015 | $145.14M | $-471,000 | -0.32% |
| Q1 2015 | $145.61M | $-5.58M | -3.69% |
| Q4 2014 | $151.19M | +$4.82M | +3.29% |
| Q3 2014 | $146.37M | $-29.17M | -16.62% |
| Q2 2014 | $175.54M | +$29.93M | +20.56% |
| Q1 2014 | $145.61M | $-4.11M | -2.75% |
| Q4 2013 | $149.73M | $-4.18M | -2.71% |
| Q3 2013 | $153.91M | +$2.96M | +1.96% |
| Q2 2013 | $150.94M | +$2.88M | +1.94% |
| Q1 2013 | $148.06M | +$90.77M | +158.43% |
| Q4 2012 | $57.29M | $-6.15M | -9.69% |
| Q3 2012 | $63.44M | $-6.70M | -9.55% |
| Q2 2012 | $70.14M | $-12.86M | -15.50% |
| Q1 2012 | $83.01M | $-10.85M | -11.56% |
| Q4 2011 | $93.86M | $-9.96M | -9.59% |
| Q3 2011 | $103.81M | $-2.93M | -2.75% |
| Q2 2011 | $106.75M | +$2.26M | +2.16% |
| Q1 2011 | $104.49M | $-8.79M | -7.76% |
| Q4 2010 | $113.27M | +$9.36M | +9.00% |
| Q3 2010 | $103.92M | $-14.15M | -11.99% |
| Q2 2010 | $118.07M | $-267,000 | -0.23% |
| Q1 2010 | $118.34M | $-9.66M | -7.55% |
| Q4 2009 | $128.00M | +$55.30M | +76.08% |
| Q3 2009 | $72.69M | +$20.33M | +38.83% |
| Q2 2009 | $52.36M | $-15.80M | -23.18% |
| Q1 2009 | $68.16M | +$11.50M | +20.30% |
| Q4 2008 | $56.66M | $-17.47M | -23.57% |
| Q3 2008 | $74.13M | $-24.97M | -25.20% |
| Q2 2008 | $99.11M | +$26.07M | +35.70% |
| Q1 2008 | $73.03M | $-21.55M | -22.79% |
| Q4 2007 | $94.59M | $-9.63M | -9.24% |
| Q3 2007 | $104.21M | $-15.61M | -13.02% |
| Q2 2007 | $119.82M | +$100.74M | +528.11% |
| Q1 2007 | $19.08M | $-14.15M | -42.60% |
| Q4 2006 | $33.23M | +$8.14M | +32.45% |
| Q3 2006 | $25.09M | +$17.43M | +227.55% |
| Q4 2005 | $7.66M | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy